» Articles » PMID: 33995344

Immunosuppressive Mechanisms of Regulatory B Cells

Overview
Journal Front Immunol
Date 2021 May 17
PMID 33995344
Citations 126
Authors
Affiliations
Soon will be listed here.
Abstract

Regulatory B cells (Bregs) is a term that encompasses all B cells that act to suppress immune responses. Bregs contribute to the maintenance of tolerance, limiting ongoing immune responses and reestablishing immune homeostasis. The important role of Bregs in restraining the pathology associated with exacerbated inflammatory responses in autoimmunity and graft rejection has been consistently demonstrated, while more recent studies have suggested a role for this population in other immune-related conditions, such as infections, allergy, cancer, and chronic metabolic diseases. Initial studies identified IL-10 as the hallmark of Breg function; nevertheless, the past decade has seen the discovery of other molecules utilized by human and murine B cells to regulate immune responses. This new arsenal includes other anti-inflammatory cytokines such IL-35 and TGF-β, as well as cell surface proteins like CD1d and PD-L1. In this review, we examine the main suppressive mechanisms employed by these novel Breg populations. We also discuss recent evidence that helps to unravel previously unknown aspects of the phenotype, development, activation, and function of IL-10-producing Bregs, incorporating an overview on those questions that remain obscure.

Citing Articles

Tumor-infiltrating B cells in non-small cell lung cancer: current insights and future directions.

Jiang S, Zhu D, Wang Y Cancer Cell Int. 2025; 25(1):68.

PMID: 40011889 PMC: 11866835. DOI: 10.1186/s12935-025-03668-3.


Revealing the role of regulatory b cells in cancer: development, function and treatment significance.

Ye R, Li S, Li Y, Shi K, Li L Cancer Immunol Immunother. 2025; 74(4):125.

PMID: 39998678 PMC: 11861783. DOI: 10.1007/s00262-025-03973-w.


Immune Cell Interactions and Immune Checkpoints in the Tumor Microenvironment of Gastric Cancer.

Cozac-Szoke A, Cozac D, Negovan A, Tinca A, Vilaia A, Cocuz I Int J Mol Sci. 2025; 26(3).

PMID: 39940924 PMC: 11818890. DOI: 10.3390/ijms26031156.


Organ-based characterization of B cells in patients with systemic lupus erythematosus.

Wang Y, Zhao R, Liang Q, Ni S, Yang M, Qiu L Front Immunol. 2025; 16:1509033.

PMID: 39917309 PMC: 11798990. DOI: 10.3389/fimmu.2025.1509033.


The role of immunity in insulin resistance in patients with polycystic ovary syndrome.

Zhang Q, Yang Z, Ou X, Zhang M, Qin X, Wu G Front Endocrinol (Lausanne). 2025; 15:1464561.

PMID: 39911236 PMC: 11797073. DOI: 10.3389/fendo.2024.1464561.


References
1.
Defuria J, Belkina A, Jagannathan-Bogdan M, Snyder-Cappione J, Carr J, Nersesova Y . B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc Natl Acad Sci U S A. 2013; 110(13):5133-8. PMC: 3612635. DOI: 10.1073/pnas.1215840110. View

2.
Rojas O, Probstel A, Porfilio E, Wang A, Charabati M, Sun T . Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10. Cell. 2019; 176(3):610-624.e18. PMC: 6903689. DOI: 10.1016/j.cell.2018.11.035. View

3.
Li G, WuLan H, Song Z, Paik P, Tsao M, Goodman G . Regulatory B Cell Function Is Suppressed by Smoking and Obesity in H. pylori-Infected Subjects and Is Correlated with Elevated Risk of Gastric Cancer. PLoS One. 2015; 10(7):e0134591. PMC: 4520600. DOI: 10.1371/journal.pone.0134591. View

4.
Jeffries M, Obr A, Urbanek K, Fyffe-Maricich S, Wood T . Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis. ASN Neuro. 2020; 12:1759091420971916. PMC: 7691909. DOI: 10.1177/1759091420971916. View

5.
Nagafuchi H, Wakisaka S, Takeba Y, Takeno M, Sakane T, Suzuki N . Aberrant expression of Fas ligand on anti-DNA autoantibody secreting B lymphocytes in patients with systemic lupus erythematosus: "immune privilege"-like state of the autoreactive B cells. Clin Exp Rheumatol. 2002; 20(5):625-31. View